Ann: Telix ProstACT (TLX591) Expert Forum - Webcast Notification, page-15

Thanks for posting, very interesting to get some insights into 591 from an experienced panel. Nat Lenzo and Oliver Sartor were especially helpful in pointing out how 591 could be introduced to treatment in combination with chemotherapy. Also Sartor's comments about the differentiation of 591 and how the possible combination of 591 and chemo (taxane) could lead to an indication/label that better fits with the practices of oncologists in giving patients more life prolonging treatments. Certainly where overall survival rates are concerned between Pluvicto and 591 you'd have to think oncologists are going to be very interested in what 591 brings to the armamentarium if Phase 3 trial results confirm the findings of the earlier studies. Less dosing, less cost to the health system and payors, less patient discomfort, better quality of life over the progression of the disease, and longer overall survival rates. I'm more confident now that 591 will differentiate itself distinctly from Pluvicto and that there is a space in the market for this kind of approach.